

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CANbridge Pharmaceuticals Inc.

北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON JUNE 24, 2022**

The Board hereby announces that all resolutions set out in the AGM Notice were duly passed by the Shareholders by way of a poll at the AGM held on June 24, 2022.

ANNUAL GENERAL MEETING (THE “AGM”)

Reference is made to the circular (the “**AGM Circular**”) and the notice of the AGM (the “**AGM Notice**”) of CANbridge Pharmaceuticals Inc. (the “**Company**”) both dated April 29, 2022. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the AGM Circular.

POLL RESULTS OF AGM

The Board is pleased to announce that all of the proposed resolutions as set out in the AGM Notice were duly passed by the Shareholders as ordinary resolutions and special resolutions by way of poll at the AGM held on June 24, 2022. The poll results in respect of the resolutions passed at the AGM are as follows:

ORDINARY RESOLUTIONS		NO. OF VOTES (APPROXIMATE %)	
		FOR	AGAINST
1.	To approve the audited consolidated financial statements of the Company and the reports of the directors of the Company (the “ Directors ”) and auditor of the Company for the year ended December 31, 2021.	331,495,490 (100%)	0 (0%)
2.	(i) To re-elect Dr. Kan Chen as a non-executive Director.	331,495,490 (100%)	0 (0%)
	(ii) To re-elect Mr. Peng Kuan Chan as an independent non-executive Director.	331,495,490 (100%)	0 (0%)
	(iii) To re-elect Dr. Lan Hu as an independent non-executive Director.	331,495,490 (100%)	0 (0%)
	(iv) To authorize the board (the “ Board ”) of Directors to fix the remuneration of the Directors.	331,495,490 (100%)	0 (0%)

ORDINARY RESOLUTIONS		NO. OF VOTES (APPROXIMATE %)	
		FOR	AGAINST
3.	To re-appoint Ernst & Young as the auditor of the Company and to authorize the Board to fix its remuneration.	331,495,490 (100%)	0 (0%)
4.	To grant a general mandate to the Directors to issue new shares of the Company.	315,553,930 (95.19%)	15,941,560 (4.81%)
5.	To grant a general mandate to the Directors to repurchase shares of the Company.	331,495,490 (100%)	0 (0%)
6.	To extend the general mandate to issue new shares by adding the number of shares repurchased.	315,553,930 (95.19%)	15,941,560 (4.81%)
SPECIAL RESOLUTION		NO. OF VOTES (APPROXIMATE %)	
		FOR	AGAINST
7.	To approve the amendments to the memorandum and articles of association of the Company and the adoption of the new memorandum and articles of association of the Company.	331,495,490 (100%)	0 (0%)

Please refer to the AGM Notice for the full text of the resolutions above.

As more than 50% were casted in favour of each of the above ordinary resolutions numbered 1 to 6 and more than 75% of votes were casted in favour of the above special resolution numbered 7, all of the above ordinary resolutions and special resolution were duly passed as ordinary resolutions and special resolution of the Company.

GENERAL

As at the date of the AGM, the number of issued Shares was 424,191,920 Shares, which was the total number of Shares entitling the holders to attend and vote for or against the resolutions at the AGM. There were no Shares entitling the holder to attend and abstain from voting in favour of any resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules. No Shareholders were required to abstain from voting at the AGM under the Listing Rules and none of the Shareholders has stated their intention in the AGM Circular to vote against or to abstain from voting on any of the resolutions proposed at the AGM.

The Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking. All Directors, namely Dr. James Qun Xue, Dr. Kan Chen, Dr. Derek Paul Di Rocco, Mr. Xiao Le, Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu, attended the AGM.

By order of the Board
CANbridge Pharmaceuticals Inc.
Dr. James Qun Xue
Chairman

Hong Kong, June 24, 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. James Qun Xue as executive Director; Dr. Kan Chen, Dr. Derek Paul Di Rocco and Mr. Xiao Le as non-executive Directors; and Mr. James Arthur Geraghty, Dr. Richard James Gregory, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.